This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
IFPMA views on the strategic use of information IFPMA views on the strategic use of information for sustainable innovation and health policiesfor sustainable innovation and health policies
Guilherme Cintra, Policy AnalystGuilherme Cintra, Policy AnalystIntellectual Property and Trade, IFPMAIntellectual Property and Trade, IFPMA
Non-profit NGO founded in 1968Non-profit NGO founded in 1968
Represents R&D-based pharmaceutical industry worldwideRepresents R&D-based pharmaceutical industry worldwide
Based in Geneva, official observer status with UN, including the Based in Geneva, official observer status with UN, including the World Health Organization, also WIPO, WTO, etc.World Health Organization, also WIPO, WTO, etc.
AIM: global policy environment favoring innovation in medicine,AIM: global policy environment favoring innovation in medicine,for the benefit of patients around the worldfor the benefit of patients around the world
IFPMA Membership:IFPMA Membership:
• 27 R&D-based biopharmaceutical companies (Europe, India, Japan & USA) 27 R&D-based biopharmaceutical companies (Europe, India, Japan & USA)
• 44 national Industry Associations, from all 5 continents44 national Industry Associations, from all 5 continents
IFPMA Influenza Vaccine Supply International Task ForceIFPMA Influenza Vaccine Supply International Task Force
The pharmaceutical industry and policymakers in both The pharmaceutical industry and policymakers in both developed and developing countries share the same objective: developed and developing countries share the same objective: the development and then the widest possible access to new the development and then the widest possible access to new drugsdrugs
Patent Landscaping Project will help policymakers in obtaining Patent Landscaping Project will help policymakers in obtaining solid information on IP practices in health areasolid information on IP practices in health area
But to maximize their innovation and access strategies, But to maximize their innovation and access strategies, policymakers should be aware of the special characteristics of policymakers should be aware of the special characteristics of the pharmaceutical industrythe pharmaceutical industry
• Current global IP system makes possible the constant discovery of new Current global IP system makes possible the constant discovery of new drugs, which after a period of exclusivity will become off-patent and drugs, which after a period of exclusivity will become off-patent and open to generic competition. open to generic competition.
• Nevertheless, there is room for strategic partnerships to address Nevertheless, there is room for strategic partnerships to address specific health needs of developing countriesspecific health needs of developing countries
R&D and Access: common goalsR&D and Access: common goals
The long R&D process (2)The long R&D process (2) R&D requires skilled workforce, good infrastructure, legal R&D requires skilled workforce, good infrastructure, legal
framework, etc. framework, etc. Modern pharmaceutical R&D requires a large network of Modern pharmaceutical R&D requires a large network of
collaborators in different countries. Only large private collaborators in different countries. Only large private sector companies manage to do in-house all the different sector companies manage to do in-house all the different phases of the R&D process.phases of the R&D process.
The R&D of a single drug can cost from US$800mi to The R&D of a single drug can cost from US$800mi to US$1.3bi. US$1.3bi.
Research institutions and companies in developing Research institutions and companies in developing countries should try to participate in collaborative R&D countries should try to participate in collaborative R&D networks in order to get the best synergy possible.networks in order to get the best synergy possible.
Patents are not a barrier to accessPatents are not a barrier to access
A patent landscape will show that most companies do not A patent landscape will show that most companies do not file for patents on pharmaceuticals in LDCs and/or have file for patents on pharmaceuticals in LDCs and/or have committed not to enforce those rights in those countries.committed not to enforce those rights in those countries.
95 % of the drugs on the WHO essential list are not 95 % of the drugs on the WHO essential list are not patentedpatented
There are many company access programs that sell There are many company access programs that sell pharmaceuticals at cost or donate them to a large pharmaceuticals at cost or donate them to a large number of developing countries (for a list of some of number of developing countries (for a list of some of these programs see these programs see http://www.ifpma.org/healthpartnerships)http://www.ifpma.org/healthpartnerships)
Information for good policiesInformation for good policies
More than just “what, where and by whom,” the critical More than just “what, where and by whom,” the critical information needed for sound health and innovation information needed for sound health and innovation policies in developing countries is:policies in developing countries is:• What is the scientific capacity of the country; what kind of What is the scientific capacity of the country; what kind of
technology transfer would be more effective and how to attract it technology transfer would be more effective and how to attract it • How to plug-into collaborative R&D networksHow to plug-into collaborative R&D networks• Examples of R&D partnerships that could be emulatedExamples of R&D partnerships that could be emulated• How to improve procurement practicesHow to improve procurement practices
• How to benefit from the existing industry access programs and How to benefit from the existing industry access programs and
other funding mechanisms (e.g. Global Fund).other funding mechanisms (e.g. Global Fund).